BridgeBio Pharma Inc. (BBIO) Appoints Hannah Valantine to its Boar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures tick up as investors weigh earnings; PayPal jumps
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise 1% as hostilities worsen in the Middle East
- Dollar on back foot as softer US inflation dims Fed hike bets
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors
October 25, 2021 7:30 AM EDTPALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to... More
